US panel gives nod to GSK/Genmab's Arzerra for leukaemia
01 June 2009
Sue Sutter
GlaxoSmithKline/
Genmab's anti-CD20 monoclonal antibody Arzerra (ofatumumab) is reasonably likely to have a clinical benefit in heavily pretreated patients with chronic lymphocytic leukaemia (CLL), the US
FDA's outside advisors say.
In a 10 to three vote, the oncologic drugs advisory committee...
Please Login to read the full article.
01 June 2009
Sue Sutter
In a 10 to three vote, the oncologic drugs advisory committee...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US judgement in anti-CD20 Mab suit favours GSK's Arzerra: Genentech/Biogen to appeal
- Onyx carfilzomib NDA accepted by FDA, but review time up in the air
- Genmab winds down zalutumumab in absence of partner
- Genentech, Biogen appeal US judgement favouring GSKin anti-CD20 Mab infringement suit
ANALYSIS
Other Informa Analysis
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
